Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

 
GLENMARK Technical Analysis
5
As on 25th Apr 2024 GLENMARK SHARE Price closed @ 1080.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 808.65 & Strong Buy for SHORT-TERM with Stoploss of 945.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GLENMARKSHARE Price

Open 1071.00 Change Price %
High 1096.00 1 Day 9.35 0.87
Low 1070.95 1 Week 38.50 3.70
Close 1080.30 1 Month 129.30 13.60
Volume 1101089 1 Year 562.15 108.49
52 Week High 828.60 | 52 Week Low 352.45
 
GLENMARK CURRENT MONTH FUTURE
Close 1079.95
Contracts Traded 1175225
Open Intrest 208075
Change In O.I -63.99 %
Lot Size 725
GLENMARK CURRENT MONTH OPTION
Most Active Call 1100.00
Most Active put 1060.00
Highest O.I Buildup Call 1100.00
Highest O.I Buildup Put 1000.00
Expiry Date 2024-04-25
GLENMARK ALL MONTHS OPTIONS
For All GLENMARK Options Click Here
 
NSE INDIA Most Active Stocks
IDEA 13.90 6.11%
YESBANK 25.95 1.96%
KOTAKBANK 1642.45 -10.87%
SOUTHBANK 30.40 4.47%
SAIL 164.95 0.18%
PNB 135.90 2.18%
TATASTEEL 167.70 1.30%
AXISBANK 1127.00 6.00%
IRFC 150.25 0.84%
IOB 66.90 5.77%
 
NSE INDIA Top Gainers Stocks
ROML 75.65 19.98%
POWERINDIA 9329.50 13.60%
GPTINFRA 211.80 12.51%
NEOGEN 1557.75 12.25%
PNC 65.00 11.02%
PNC 65.00 11.02%
PNC 65.00 11.02%
PNC 65.00 11.02%
MOIL 430.70 10.88%
GODFRYPHLP 3449.70 10.17%
 
NSE INDIA Top Losers Stocks
KOTAKBANK 1642.45 -10.87%
GLS 750.50 -9.20%
EXCEL 0.50 -9.09%
DALBHARAT 1806.45 -7.97%
WEIZMANIND 132.50 -6.85%
5PAISA 536.35 -6.77%
CELEBRITY 19.85 -6.59%
BBL 3135.00 -5.60%
BBL 3135.00 -5.60%
BBL 3135.00 -5.60%
 
 
GLENMARK
Daily Charts		 GLENMARK
Intraday Charts		 Whats New @
Bazaartrend		 GLENMARK
Free Analysis
 
GLENMARK Important Levels Intraday
RESISTANCE1128.57
RESISTANCE1113.09
RESISTANCE1103.52
RESISTANCE1093.95
SUPPORT1066.65
SUPPORT1057.08
SUPPORT1047.51
SUPPORT1032.03
 
GLENMARK Target April 2024
Share
4th UP Target1249.82
3rd UP Target1144.14
2nd UP Target1078.82
1st UP Target1013.5
1st DOWN Target827.11
2nd DOWN Target761.78
3rd DOWN Target696.46
4th DOWN Target590.78
 
GLENMARK Weekly Target
4th UP Target1122.46
3rd UP Target1091.65
2nd UP Target1072.61
1st UP Target1053.57
1st DOWN Target999.23
2nd DOWN Target980.19
3rd DOWN Target961.15
4th DOWN Target930.34
 
GLENMARK Target2024
4th UP Target1848.96
3rd UP Target1529.85
2nd UP Target1332.61
1st UP Target1135.36
1st DOWN Target572.54
2nd DOWN Target375.29
3rd DOWN Target178.05
4th DOWN Target-141.06
 
 
GLENMARK Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
 Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is 30.48 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -73.24 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 245.00
10 Day Avg Volume Traded 14.34 % More then 10 Day Average Volume
 
GLENMARK Other Details
Segment EQ
Market Capital 142623457280.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
GLENMARK Address
GLENMARK
 
GLENMARK Latest News
 
Your Comments and Response on Glenmark Pharmaceuticals Limited
 
GLENMARK Business Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India. Address: Glenmark House, Mumbai, India, 400099
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service